1. Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
- Author
-
Shepherd R. Singer, M.D., Frederick J. Angulo, Ph.D., David L. Swerdlow, M.D., John M. McLaughlin, Ph.D., Itay Hazan, M.Sc., Netanel Ginish, B.S, Emilia Anis, M.D., Ella Mendelson, Ph.D., Orna Mor, Ph.D., Neta S Zuckerman, Ph.D., Oran Erster, Ph.D., Jo Southern, Ph.D., Kaijie Pan, M.S., Gabriel Mircus, Ph.D., Marc Lipsitch, D.Phil., Eric J. Haas, M.D., Luis Jodar, Ph.D., Yeheskel Levy, M.D., and Sharon Alroy-Preis, M.D.
- Subjects
COVID-19 ,SARS-CoV-2 ,vaccine effectiveness ,prevention ,mRNA vaccines ,variant Beta (B.1.351) ,Medicine (General) ,R5-920 - Abstract
Background: SARS-CoV-2 variant Beta (B.1.351) was designated as a Variant of Concern (VoC) after becoming the dominant strain in South Africa and spreading internationally. BNT162b2 showed lower levels of neutralizing antibodies against Beta than against other strains raising concerns about effectiveness of vaccines against infections caused by Beta. We estimated BNT162b2 vaccine effectiveness (VE) against Beta infections in Israel, a country with high vaccine uptake. Methods: The Ministry of Health (MoH) identified Beta cases through mandatory reporting of SARS-CoV-2 cases and whole genome sequencing (WGS) of specimens from vaccination-breakthrough infections, reinfections, arriving international travelers, and a selection of other infected persons. A cohort analysis was conducted of exposure events of contacts of primary Beta cases. WGS was conducted on available PCR-positive specimens collected from contacts. VE estimates with 95% confidence intervals (CIs) against confirmed and probable Beta infections were determined by comparing infection risk between unvaccinated and fully-vaccinated (≥7 days after the second dose) contacts, and between unvaccinated and partially-vaccinated (
- Published
- 2021
- Full Text
- View/download PDF